Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2012, Article ID 356128, 6 pages
http://dx.doi.org/10.1100/2012/356128
Research Article

Prognostic Value of Hepatocyte Growth Factor, Syndecan-1, and Osteopontin in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance

1Department of Internal Medicine III, Palacky University and University Hospital Olomouc, 775 20 Olomouc, Czech Republic
2Department of Clinical Biochemistry, Palacky University and University Hospital Olomouc, 775 20 Olomouc, Czech Republic
3Department of Biophysics and Statistics, Palacky University of Olomouc, 775 20 Olomouc, Czech Republic

Received 29 October 2011; Accepted 1 December 2011

Academic Editors: M. Borset and D. H. Dinh

Copyright © 2012 Jiri Minarik et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. V. Scudla, P. Petrova, J. Minarik, T. Pika, and J. Bacovsky, “Analysis of the serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and different stages of multiple myeloma,” Neoplasma, vol. 58, no. 6, pp. 499–506, 2011. View at Google Scholar
  2. M. G. Alexandrakis, F. H. Passam, A. Sfiridaki, E. Kandidaki, P. Roussou, and D. S. Kyriakou, “Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity,” American Journal of Hematology, vol. 72, no. 4, pp. 229–233, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. N. F. Andersen, T. Standal, J. L. Nielsen et al., “Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival,” British Journal of Haematology, vol. 128, no. 2, pp. 210–217, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. Y. Saeki, T. Mima, T. Ishii et al., “Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications,” British Journal of Haematology, vol. 123, no. 2, pp. 263–270, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Seidel, S. Lenhoff, S. Brabrand et al., “Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapy,” British Journal of Haematology, vol. 119, no. 3, pp. 672–676, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Vacca, D. Ribatti, A. M. Roccaro, A. Frigeri, and F. Dammacco, “Bone marrow angiogenesis in patients with active multiple myeloma,” Seminars in Oncology, vol. 28, no. 6, pp. 543–550, 2001. View at Google Scholar · View at Scopus
  7. S. V. Rajkumar, T. Leong, P. C. Roche et al., “Prognostic value of bone marrow angiogenesis in multiple myeloma,” Clinical Cancer Research, vol. 6, no. 8, pp. 3111–3116, 2000. View at Google Scholar · View at Scopus
  8. A. Vacca, D. Ribatti, L. Roncali et al., “Bone marrow angiogenesis and progression in multiple myeloma,” British Journal of Haematology, vol. 87, no. 3, pp. 503–508, 1994. View at Google Scholar · View at Scopus
  9. J. R. Molina and S. V. Rajkumar, “Bone marrow angiogenesis in multiple myeloma: closing in on the loop,” Haematologica, vol. 88, no. 2, pp. 122–124, 2003. View at Google Scholar · View at Scopus
  10. O. Sezer, K. Niemöller, J. Eucker et al., “Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma,” Annals of Hematology, vol. 79, no. 10, pp. 574–577, 2000. View at Google Scholar · View at Scopus
  11. W. Du, Y. Hattori, T. Yamada et al., “NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells: molecular targeting of angiogenic growth factor,” Blood, vol. 109, no. 7, pp. 3042–3049, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. R. U. Holt, U. M. Fagerli, V. Baykov et al., “Hepatocyte growth factor promotes migration of human myeloma cells,” Haematologica, vol. 93, no. 4, pp. 619–622, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Sato, Y. Hakeda, Y. Yamaguchi et al., “Hepatocyte growth factor is involved in formation of osteoclast-like cells mediated by clonal stromal cells (MC3T3-G2/PA6),” Journal of Cellular Physiology, vol. 164, no. 1, pp. 197–204, 1995. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Fuller, J. Owens, and T. J. Chambers, “The effect of hepatocyte growth factor on the behaviour of osteoclasts,” Biochemical and Biophysical Research Communications, vol. 212, no. 2, pp. 334–340, 1995. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Standal, N. Abildgaard, U. M. Fagerli et al., “HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma,” Blood, vol. 109, no. 7, pp. 3024–3030, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Pour, L. Kovářová, T. Buchler et al., “Evaluation of HGF and endostatin in the bone marrow of patients with multiple myeloma and the effect of peripheral blood admixture,” Scripta Medica Facultatis Medicae Universitatis Brunensis Masarykianae, vol. 82, no. 2, pp. 123–126, 2009. View at Google Scholar · View at Scopus
  17. C. Seidel, M. Børset, I. Turesson, N. Abildgaard, A. Sundan, and A. Waage, “Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma,” Blood, vol. 91, no. 3, pp. 806–812, 1998. View at Google Scholar · View at Scopus
  18. O. Sezer, C. Jakob, J. Eucker et al., “Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma,” European Journal of Haematology, vol. 66, no. 2, pp. 83–88, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. L. Pour, H. Svachova, Z. Adam et al., “Pretreatment hepatocyte growth factor and thrombospondin-1 levels predict response to high-dose chemotherapy for multiple myeloma,” Neoplasma, vol. 57, no. 1, pp. 29–34, 2010. View at Google Scholar · View at Scopus
  20. H. Šváchová, L. Pour, M. Almáša et al., “Concentration of hepatocyte growth factor and thrombospondin predict treatment response in patients with multiple myeloma,” Transfuze a Hematologie Dnes, vol. 16, no. 1, pp. 30–34, 2010 (Czech). View at Google Scholar
  21. S. Colla, F. Morandi, M. Lazzaretti et al., “Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients,” Leukemia, vol. 19, no. 12, pp. 2166–2176, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Standal, H. Hjorth-Hansen, T. Rasmussen et al., “Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma,” Haematologica, vol. 89, no. 2, pp. 174–182, 2004. View at Google Scholar · View at Scopus
  23. D. F. Robbiani, K. Colon, S. Ely, S. Ely, M. Chesi, and P. L. Bergsagel, “Osteopontin dysregulation and lytic bone lesions in multiple myeloma,” Hematological Oncology, vol. 25, no. 1, pp. 16–20, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Sfiridaki, S. Miyakis, C. Pappa et al., “Circulating osteopontin: a dual marker of bone destruction and angiogenesis in patients with multiple myeloma,” Journal of Hematology and Oncology, vol. 4, article 22, 2011. View at Publisher · View at Google Scholar
  25. Y. Yang, S. Yaccoby, W. Liu et al., “Soluble syndecan-1 promotes growth of myeloma tumors in vivo,” Blood, vol. 100, no. 2, pp. 610–617, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Purushothaman, T. Uyama, F. Kobayashi et al., “Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis,” Blood, vol. 115, no. 12, pp. 2449–2457, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Seidel, A. Sundan, M. Hjorth et al., “Serum syndecan-1: a new independent prognostic marker in multiple myeloma,” Blood, vol. 95, no. 2, pp. 388–392, 2000. View at Google Scholar · View at Scopus
  28. V. Ščudla, M. Budíková, P. Petrová et al., “Analysis of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and multiple myeloma,” Klinicka Onkologie, vol. 23, no. 3, pp. 171–181, 2010 (Czech). View at Google Scholar